# THE CLOROX COMPANY (CLX) · Edgar & Edgarette company card

> The Clorox Company (CLX) grew revenue 0.2% in FY2025 to $7.1 billion, equity 5.8% of assets, and dividend per share up 16 years running. Every figure is from the company’s own annual report filed with the SEC.

SEC CIK 21076 · fiscal year ended 2025-06-30 · 5 audited years read · [page](https://www.pops4.com/boards/company/CLX) · [JSON](https://www.pops4.com/boards/company/CLX.json)

## Figures, as filed in the 10-K

| Measure | Value |
|---|---|
| Revenue | $7.1B |
| Revenue growth, 1 year | 0.2% |
| Revenue growth per year | -0.8% |
| Operating margin | — |
| Net margin | 11.6% |
| Operating cash flow | $981M |
| Capital spending | $220M |
| Free cash flow | $761M |
| Cash | $167M |
| Long-term debt | $2.5B |
| Total assets | $5.6B |
| Total equity | $321M |
| Equity ÷ assets | 5.8% |
| Return on equity | 256.7% |
| Dividend per share | $4.88 |
| Dividend years rising | 16 |

## Readings, computed from those figures

- Piotroski F: 7 of 9 (solid)
- Beneish M: -2.51 (below the −1.78 line)
- Health Harbor boat: Sound ship · one warning sign · liabilities exceed assets (often from years of share buybacks, not always distress)
- Cash Compass: Steady earner · steady and paying a dividend, with average cash

## Edgarette's reading

Exposure: revenue $7.1B (FY2025), total debt $2.5B. Experience: revenue up 0.2% on the year, down 0.8% a year over 4 years. Soundness: equity 5.8% of assets, return on equity 256.7%, payout 73.1% of profit, dividend per share up 16 years running. Credibility: four or more audited years, reasonable weight. Range: 80% of past cases like this landed between $6.3B and $7.6B next year (method v4.1: its own 4-year record of growth weighed at 50% against $1B–10B filers; across 2019–2025, 69.0% landed inside, 83.4% on the one year the method never saw). In a shock year the stress range is $5.9B to $8.1B. A statistical range, not company guidance. Against peers (14 filers, $50M+ revenue, its industry group): growth 0.2% against 0.8%.

## Health Watch, last 12 months

- Item 5.02 Director or officer change: 3, latest 2026-10-29 ([filing](https://www.sec.gov/Archives/edgar/data/21076/000120677426000586/0001206774-26-000586-index.htm))

## Recent filings

- 10-Q · filed 2026-11-02 · [filing](https://www.sec.gov/Archives/edgar/data/21076/000002107626000046/0000021076-26-000046-index.htm)
- 8-K · filed 2026-11-02 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/21076/000002107626000044/0000021076-26-000044-index.htm)
- 8-K · filed 2026-10-29 · 5.02 Departure or Election of Directors; Appointment of Officers; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/21076/000120677426000586/0001206774-26-000586-index.htm)
- DEF 14A · filed 2026-10-07 · [filing](https://www.sec.gov/Archives/edgar/data/21076/000155278126000516/0001552781-26-000516-index.htm)
- 10-K · filed 2026-08-07 · [filing](https://www.sec.gov/Archives/edgar/data/21076/000002107626000034/0000021076-26-000034-index.htm)
- 8-K · filed 2026-08-03 · 2.02 Results of Operations and Financial Condition; 7.01 Regulation FD Disclosure; 9.01 Financial Statements and Exhibits · [filing](https://www.sec.gov/Archives/edgar/data/21076/000002107626000028/0000021076-26-000028-index.htm)

## Sources

- facts: https://data.sec.gov/api/xbrl/companyfacts/CIK0000021076.json
- filings: https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=21076

## Cite

POPS4, Edgar & Edgarette: THE CLOROX COMPANY (CLX) company card, from the company's own SEC filings, accessed 2026-11-10, https://www.pops4.com/boards/company/CLX. CC BY 4.0. For a figure, add the filing URL under filings or sources.

DOI https://doi.org/10.5281/zenodo.23672509 · catalog https://www.pops4.com/boards/catalog.json · Figures as filed with the SEC. Card text CC BY 4.0, POPS4.

Reporting, not investment advice. No price targets and no trading recommendations.

Figures are as filed in audited 10-K reports and can move with restatements, acquisitions, disposals or a change in fiscal year. A range set from how past company-years turned out is not a promise about the next one, and says nothing about the share price.